Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV
Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection
Sponsor: Ain Shams University
This NA trial investigates Hepatitis C, Chronic and is currently completed. Ain Shams University leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ain Shams University
- Cairo University
- National Hepatology & Tropical Medicine Research Institute
- National Liver Institute, Egypt
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
For direct contact, visit the study record on ClinicalTrials.gov .